Therapeutic anti-melanoma compounds

Abstract

The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compositions of the invention.

1 - 37 . (canceled)  
     
     
         38 . An immune effector cell that has been raised in vitro or in vivo in the presence and at the expense of an antigen presenting cell that presents at least one immunogenic ligand selected from the group consisting of FLDQVAFVV (SEQ ID NO:5), FLDQVAFSV (SEQ ID NO:7), FLFLWFFEV (SEQ ID NO:9). FLDQRVFVV (SEQ ID NO:11), FLTMWPGGV (SEQ ID NO:13), FLSWEGLVV (SEQ ID NO:15). FLIWEGYVV (SEQ ID NO:17), FLDSVFNLV (SEQ ID NO:19), and FLLWEGLVV (SEQ ID NO:21) in the context of an MHC molecule.  
     
     
         39 . A method of adoptive immunotherapy, comprising administering an effective amount of the immune effector cell of  claim 38 .  
     
     
         40 . An immune effector cell that has been raised in vitro or in vivo in the presence and at the expense of an antigen presenting cell that presents 
 (i) at least one immunogenic ligand selected from the group consisting of FLDQVAFVV (SEQ ID NO:5), FLDQVAFSV (SEQ ID NO:7), FLFLWFFEV (SEQ ID NO:9), FLDQRVFVV (SEQ ID NO:11), FLTMWPGGV (SEQ ID NO:13), FLSWEGLVV (SEQ ID NO:15), FLIWEGYVV (SEQ ID NO:17), FLDSVFNLV (SEQ ID NO:19), and FLLWEGLVV (SEQ ID NO:21) and, additionally    (ii) FLDQVPFSV (SEQ ID NO:3), in the context of an MHC molecule.    
     
     
         41 . The immune effector cell of  claim 38 , wherein said immune effector cell is a T cell.  
     
     
         42 . The immune effector cell of  claim 42 , wherein said immune effector cell is a T cell.